Zhejiang Dayang Biotech Group Co Working Capital to Net Assets Ratio
Zhejiang Dayang Biotech Group Co working capital to net assets ratio. Zhejiang Dayang Biotech Group Co (003017) has a Working Capital to Net Assets ratio of 12.5% as of March 2026. Working capital of CN¥146.61 Million (current assets of CN¥797.84 Million minus current liabilities of CN¥651.23 Million) is measured against net assets of CN¥1.17 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Zhejiang Dayang Biotech Group Co tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Zhejiang Dayang Biotech Group Co (2013–2025)
Working capital to net assets ratio of Zhejiang Dayang Biotech Group Co from 2013 to 2025. This chart shows how Zhejiang Dayang Biotech Group Co's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 12.5%, reflecting working capital of CN¥146.61 Million against net assets of CN¥1.17 Billion CNY. See how many days can Zhejiang Dayang Biotech Group Co fund operations to measure how many days the company can operate on defensive assets alone.
Zhejiang Dayang Biotech Group Co Working Capital to Net Assets Ratio by Year (2013–2025)
Zhejiang Dayang Biotech Group Co working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Dayang Biotech Group Co from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 003017 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 12.2% | CN¥138.74 Million | CN¥1.14 Billion | CN¥771.31 Million | CN¥632.58 Million | ▲ +0.5 pp |
| 2024 | 11.7% | CN¥122.85 Million | CN¥1.05 Billion | CN¥690.55 Million | CN¥567.70 Million | ▼ -11.3 pp |
| 2023 | 22.9% | CN¥231.38 Million | CN¥1.01 Billion | CN¥661.63 Million | CN¥430.26 Million | ▼ -2.4 pp |
| 2022 | 25.4% | CN¥249.92 Million | CN¥985.05 Million | CN¥728.16 Million | CN¥478.24 Million | ▼ -17.6 pp |
| 2021 | 43.0% | CN¥425.53 Million | CN¥990.71 Million | CN¥742.70 Million | CN¥317.16 Million | ▼ -9.0 pp |
| 2020 | 52.0% | CN¥497.78 Million | CN¥958.13 Million | CN¥698.29 Million | CN¥200.51 Million | ▲ +24.9 pp |
| 2019 | 27.1% | CN¥134.95 Million | CN¥498.09 Million | CN¥265.59 Million | CN¥130.64 Million | ▼ -0.9 pp |
| 2018 | 27.9% | CN¥123.14 Million | CN¥440.62 Million | CN¥269.92 Million | CN¥146.77 Million | ▲ +10.2 pp |
| 2017 | 17.7% | CN¥59.91 Million | CN¥337.71 Million | CN¥223.79 Million | CN¥163.88 Million | ▲ +32.2 pp |
| 2016 | -14.5% | CN¥-33.18 Million | CN¥229.35 Million | CN¥193.87 Million | CN¥227.05 Million | ▲ +5.2 pp |
| 2015 | -19.7% | CN¥-41.33 Million | CN¥209.76 Million | CN¥207.79 Million | CN¥249.12 Million | ▲ +0.3 pp |
| 2014 | -20.0% | CN¥-39.30 Million | CN¥196.87 Million | CN¥227.13 Million | CN¥266.43 Million | ▼ -8.3 pp |
| 2013 | -11.7% | CN¥-21.85 Million | CN¥187.42 Million | CN¥232.08 Million | CN¥253.93 Million | — |